Reconstructive REVIEW

OFFICIAL JOURNAL OF THE

Joint Implant Surgery and Research Foundation
Strategic Alliance with

Joint Implant Surgeons

Orthopaedic Surgeons Specializing in Joint Replacement and Joint Preservation of the Hip, Knee, and Shoulder
DARF, founded in 2005 by Dr. Thomas K. Donaldson, has a focus on outcome studies and basic science with major emphasis on implant retrievals. His ongoing collaboration with Ian Clarke, PhD provides a synergy between the laboratory and clinical surgical science. Both men are Board Members of JISRF and have a significant working relationship with its Executive Director Timothy McTighe Dr. HS (hc).

JISRF, founded in 1971, has had significant experience with continuing medical education, product development, and clinical surgical evaluation of total joint implant devices.

The long term relationships JISRF has with total joint surgeons world wide and the experience of its Co-Directors and research evaluation equipment of the DARF Retrieval Center make for a strong long-term relationship.

Together both groups will provide unprecedented analysis of your Retrievals.

www.jisrf.org • www.darfcenter.org
## JISRF Board Members
Charles O. Bechtol, MD  
(Founder 1971-1998)
Louise Bechtol, R.N.  
(Founding member)
Keith Berend, MD
Declan Brazil, PhD
Hugh U. Cameron, MB, ChB
Jack Diamond, Esq.
Dr. John M. Harrison AM
John Keggi, MD
Louis Keppler, MD
Edward James McPherson, MD
Timothy McTighe, Dr. HS (hc)

## Lifetime Achievement Honorees
- 1991 Charles O. Bechtol, MD
- 1992 Charles O. Townley, MD
- 1993 Irwin S. Leinbach, MD
- 1994 Bruce D. Shepherd, MB
- 1995 James E. Bateman, MD
- 1996 Roderick H. Turner, MD
- 1997 William R. Murray, MD
- 2003 Thomas H. Mallory, MD
- 2007 Ian Clarke, PhD
- 2010 Kristaps J. Keggi, MD
- 2014 John H. Harrison, PM, MD

## Clinical/Surgical Research Advisors:
- David Campbell, MD
- Michael Christie, MD
- Terry Clyburn, MD
- Kristaps J. Keggi, MD
- Robert Kennon, MD
- Evert Smith, MD
- Adrian van der Rijt, MD

## Reviewers
The goal of JISRF and Reconstructive Review is to provide peer-reviewed, open-access orthopaedic articles focusing on total joint arthroplasty. To achieve this goal we rely on those individuals who are willing to take on the responsibility, and privilege, to review articles written by their peers. The following is Reconstructive Review’s current list of reviewers.

| Charles Alexander | C. Anderson Engh | David Mauerhan | Raj Sinha |
| Daniel Allison | Mark Froimson | Michael Mayor | Evert Smith |
| Hani Alnakhli | Jerry Gorski | Joseph McCarthy | Rami Sorial |
| Christopher Anderson | Kenneth Greene | Lorcan McGonagle | Panayot Tanev |
| Asaad Asaad | William Griffin | Harry McKellop | Panayot Tanev, Jr. |
| Keith Berend | Ronald Hillock | Edward McPherson | Richard Tarr |
| Declan Brazil | Kirby Hitt | Timothy McTighe | Jeffery Taylor |
| Warwick Bruce | John Ireland | Jon Minter | Robert Thornberry |
| Hugh Cameron | Robert Jamieson | Russell Nevins | Allen Turnbull |
| David Campbell | Riyaz Jinnah | Steven Nishiyama | Anthony Unger |
| Edward Cheal | Maurice Jove | Philip Noel | Adrian van der Rijt |
| Michael Christie | Stephen Kayiaros | Mary O’Connor | Bradley Walter |
| Ian Clarke | John Keggi | Julio Palacio | William Walter |
| Terry Clyburn | Kristaps Keggi | Christopher Peters | Bill Walter |
| Simon Coffey | Robert Kennon | Derek Pupello | Andrew Wassef |
| Richard Cook | Louis Kepper | Lee Rubin | Duncan Whitwell |
| Paul Della Torre | Stefan Kreuzer | Mark Sacaris | Sumesh Zingde |
| Paul DiCesare | Lafayette Lage | Lewis Samuels | |
| Matt Dipane | Jeremy Latham | Kent Samuelson | |
| Thomas Donaldson | Audley Mackel | Frank Schmidt | |
| Scott Dunitz | Michael Manley | W. Norman Scott | |
The Reconstructive Review (ISSN 2331-2262 print, ISSN 2331-2270 online) will be published four times a year by the Joint Implant Surgery & Research Foundation, 46 Chagrin Plaza #117, Chagrin Falls, Ohio 44023.

Editorial Correspondence

Please direct any requests for inclusion, editorial comments or questions to Timothy McTighe, Dr. HS (hc), Executive Director, JISRF, 46 Chagrin Plaza #117, Chagrin Falls, Ohio 44023, tmct@jisrf.org.

Correspondence

Direct any questions regarding the submission process, or requests for reprints to David Faroo, Director of Communications, JISRF, 46 Chagrin Plaza #117, Chagrin Falls, Ohio 44023, dfaroo@jisrf.org.

There is no subscription charge for receipt of this publication. This is done as a service keeping with the overall mission of JISRF.

For information on how to submit articles to the Reconstructive Review please review the following or visit https://www.reconstructivereview.org.

Submit Articles to the Reconstructive Review

Please visit ReconstructiveReview.org to submit an article for review and publication in the Reconstructive Review. All material to be considered for publication should be submitted via this online submission system.

Before submitting an article to Reconstructive Review, please follow the instructions below.

ARTICLE TYPES

Reconstructive Review accepts the following categories of articles:

• Original Articles
• Basic Science
• Case Reports
• Clinical/Surgical
• Commentary
• Controversial Issues (i.e. modularity, tapers, MoM)
• Healthcare Policy/Economics
• Reviews
• Letters to the Editor
• Surveys

The emphasis for these subjects is to address real life orthopaedics in a timely fashion and to encourage the participation from a broad range of professionals in the orthopaedic health care field.

We will strive to be responsible and reactive to the needs expressed to our editors and all members of JISRF. We anticipate our format will evolve as we move forward and gain more experience with this activity. Your opinion is a critical step to our motivation and overall success, please do not hesitate to communicate with us.

INSTRUCTIONS FOR SUBMITTING ARTICLES

Please read the following information carefully to ensure that the review and publication of your paper is as efficient and quick as possible. The editorial team reserves the right to return manuscripts that have not been submitted in accordance with these instructions.

File Formats

• All articles must be submitted as Word files (.doc/.docx) with lines of text numbered. PDF’s are not acceptable for submission.
• Figures, images, and photographs should be high quality JPG images (at least 150 dpi, 300 dpi if possible). All illustrations and line art should be at least 1200 dpi.

Article Preparation

Articles submitted will need to be divided into separate files including cover page and manuscript. Figures, images, and photographs should be submitted separately.

• Cover Page - includes article title, lists all authors that have contributed to the submission and provides all authors information including their title, full name, their association with the paper, their full postal address and email. Please list all authors in the order that you want them to appear.
• Manuscript - EXCLUDES ALL AUTHOR INFORMATION. The manuscript is used in creating the file for peer review – a double blind process. Your sub-
mission should follow this structure:
- Title
- Structured Abstract (Introduction, Materials & Methods, Results, Discussion, and Conclusion)
- Introduction
- Materials & Methods
- Results
- Discussion
- Conclusion
- References (for styles please refer to the website http://www.nlm.nih.gov/bsd/uniform_requirements.html)

- Figures, Images and Photographs - Please do not embed figures, images, and photographs in the main manuscript. They should be uploaded as individual files.

Once you have prepared your manuscript according to the information provided above, please go to our website ReconstructiveReview.org and click on the Register link. Once you have registered you will click on the Submit New Manuscript link. Detailed instructions on how to submit your manuscript can be found at ReconstructiveReview.org.

INFORMED CONSENT

Any manuscript dealing with human subjects must include a statement that proper disclosure was given and patient consent was received.

COPYRIGHT AGREEMENT

Authors retain copyright and grant the journal right of first publication with the work. Reconstructive Review follows the Creative Commons Attribution-NonCommercial CC BY-NC. This license allows anyone to download works, build upon the material, and share them with others for non-commercial purposes as long as they credit the senior author, Reconstructive Review, and the Joint Implant Surgery & Research Foundation (JISRF). An example credit would be: “Courtesy of (senior author’s name), Reconstructive Review, JISRF, Chagrin Falls, Ohio”. While works can be downloaded and shared they cannot be used commercially.

DISCLOSURE STATEMENT

As part of the online submission process, corresponding authors are required to confirm whether they or their co-authors have any disclosures to declare, and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, the authors in question will then be required to submit a completed Disclosure Statement form to the Editorial Office (editors@reconstructivereview.org). It is the Corresponding author’s responsibility to ensure that all authors adhere to this policy.

There are three statements to choose from on the Disclosure Statement form, they are:
1. No benefits or funds were received in direct or indirect support of this article.
2. Benefits or funds were received in support of this article either directly or indirectly.
3. Either family, institution I am associated with, or I have received benefits or funds either directly or indirectly regarding this article. (Examples include: Royalties, Consulting Fees, Stock Options, Equity, Institutional Funds)

Reconstructive Review Production Specifications

The Reconstructive Review is currently constructed using InDesign running on a Mac. The document is published on the web, available for download as a PDF, and printed in limited quantities.
- Trim Size: 8.5” x 11”
- Live Area: 7.25” x 9.25”
- No Bleeds

Ad Specification
- Full color or black and white - available sizes:
  - Full Page, 7.25” x 9.25”
  - Half Page Horizontal, 7.25” x 4.25”
  - Half Page Vertical, 3.25” x 9.25”

Any questions regarding these specifications should be directed to media@jisrf.org.

General Statement

The ideas, opinions and statements expressed in the Reconstructive Review do not necessarily reflect those of the publisher and or editor of this publication. Publication of advertisement does not indicate an endorsement of product or service by the publisher or editor of JISRF. The publisher and editor assume no responsibility for any injury or damage resulting out of any publication of material within the Reconstructive Review. The reader is advised to review and regard with balance any information published within this publication with regard to any medical claim, surgical technique, product features or indications and contraindications. It is the responsibility of the professional treating medical physician to review any and all information before undertaking any change of treatment for their patients.
Signature Orthopaedics is a design, development and manufacturing company for orthopaedic implants and instruments. The head office located in Sydney Australia, with offices in Europe and North America. We have years of experience in taking concepts right through design and development and into certification, whether it be the FDA, BSI or the TGA.

We are routinely supplying parts for the Hip, Knee, foot and ankle, spine, shoulder, both to the locally and international markets. With the added capability of making custom implants for specific cases, using the latest software to guarantee the perfect fit.

We are happy to design and develop both instruments and prosthesis for your needs, or we can supply one of our many FDA approved solutions as an OEM vendor. Our product, your box!

Call or email to discuss which solution is right for you!
Calibrated Femoral Tibial Spreaders

Helps separate the femur and tibia during total knee replacement surgery

- Ground Pads
- Diamond Cut Pads
- Coated Pads

PRODUCT NO:
1850  [Small w/ Grooved Pads]
1850-D  [Small w/Diamond Cut Pads]
1850-01  [Small w/Coated Pads]
1865  [Small w/ Round Pads]

PRODUCT NO:
1855  [Medium w/ Grooved Pads]
1855-D  [Medium w/Diamond Cut Pads]
1855-SL  [Medium w/ Speed Lock & Grooved Pads]
1866  [Medium w/ Round Pads]

PRODUCT NO:
1860  [Large w/ Grooved Pads]

Stulberg Leg Positioner

Provides stable positioning of the knee during surgery

PRODUCT NO:
2620

Wilson Condylar Gauge

Designed to measure the posterior femoral condyle after the posterior cuts have been made in total knee arthroplasty

PRODUCT NO:
1194

Offset Osteotomes

Designed to remove osteophytes from the posterior femoral condyles during knee arthroplasty

PRODUCT NO:
4920  [Wide]
4935  [Lotke]
4935-W  [Dennis]

Chandran Tibial Knee Retractor

Designed for use in TKA, the hook on the front of the blade acts as a stop to help prevent the retractor from deep penetration behind the tibia

PRODUCT NO:
4533

Innomed-Europe
Tel. +41 41 740 67 74
Fax +41 41 740 67 71

© 2018 Innomed, Inc.
CONTENTS

CLINICAL/SURGICAL

13 Does Implant Design Affect Hospital Metrics and Patient Outcomes? TKA Utilizing a “Fast-Track” Protocol
   Buch RG, Schroeder L, Buch R, Eberle R

17 Restoration of Femoral Condylar Anatomy for Achieving Optimum Functional Expectations: Continuation of an Earlier Study At 5-Year Minimum Follow-Up
   Durbhakula S, Durbhakula V, Durbhakula N

ORIGINAL ARTICLE

23 Techniques of Insertion and Early Clinical Impressions with a Short Curved Tissue Sparing Implant for Total Hip Arthroplasty (The French Experience)
   Venet G, Tesson A, Le Cour Grandmaison F, Fraquet N, Brazil D, McTighe T

31 Can We Improve Screening Costs in Asymptomatic Metal on Metal Total Hip Arthroplasties?
   Martin JR, Otero JE, Springer BD, Griffin WL

COMMENTARY

37 What is Considered a Conflict of Interest or What to Disclose in Lectures and Publications?
   McTighe T
Does Implant Design Affect Hospital Metrics and Patient Outcomes? TKA Utilizing a “Fast-Track” Protocol

Buch RG¹, Schroeder L², Buch R¹, Eberle R¹

Abstract

Background: “Fast-Track” protocols have been introduced in TKA with the intention to increase health care savings while maintaining or improving patient outcomes. The influence of the implant design in a “Fast-Track” setting has not been described yet. The primary goal of this study was to compare a customized implant with standard off-the-shelf (OTS) devices when utilizing a “Fast-Track” protocol.

Methods: Sixty-two (62) patients were prospectively enrolled at a single center and implanted with either a customized or a standard off-the-shelf implant resulting in thirty (30) patients being treated with an OTS design and thirty-two (32) with the customized design. The same institutional fast-track protocol was utilized on all patients and included pre-, intra-, and postoperative medical treatment. We assessed total length of stay (LOS), discharge destination and range of motion at 6-8 weeks post-op and at an average of 16 months post-op follow-up to compare the OTS implant with the customized device. Implant survivorship was assessed at a minimum of 25 months post-op.

Results: Using the fast track protocol we were able to decrease overall LOS to 2.1 days versus 3.6 days prior to introduction of the protocol. The use of the customized implant further reduced LOS significantly to 1.6 days. Significantly higher number of patients who got implanted with the customized device (66%) were discharged within 24 hours than in the OTS group (30%). Patients treated with the customized implant were found to be discharged home more often than patients treated with the OTS implants (97% vs. 80%) and achieved higher range of motion both at 6-8 weeks (114° vs. 101°) and at an average of 16 months (122° vs. 114°) than patients who got treated with the OTS device. At an average follow-up of 28 months, there was 1 implant revision in the customized group (due to tibial fracture resulting from patient fall). For the OTS group there was 1 implant revision (late infection) and 1 poly swap (due to instability).

Discussion: Based on our analysis we observed a positive influence of the customized device on patient outcomes and hospital metrics and we therefore conclude that the implant choice is an important factor for TKA in a “fast-track” setting.

Background

In the current health care environment there is an increased focus on health care savings while maintaining or improving patient outcomes. This has become an important factor for patients undergoing total knee arthroplasty (TKA) with practicing physicians constantly aiming to increase the efficiency and cost effectiveness of the proce-

Keywords: Fast Track; customized; total knee arthroplasty

Level of Evidence: AAOS Therapeutic Level II
dure. One methodology to decrease patient’s length of stay (LOS) is to incorporate a fast track protocol and thereby reducing per patient burden on the hospital. “Fast-track” has been defined as a hospitalization which provides best possible evidence-based treatment, using fewer clinical resources within a hospital stay while maintaining high patient satisfaction and few complications [1]. Success criteria have been described as reduction of perioperative morbidity, optimized pain management, shorter convalescence, a reduction in postoperative length of stay and a rapid functional recovery due to early mobilization [1-3].

Previous studies examining clinical outcomes following a fast track protocol have shown that changing patient care has its benefits and drawbacks. They have investigated various factors such as the type of anesthesia, postoperative rehabilitation and optimized pain relief that can influence faster discharge while maintaining optimum patient care [4-6]. Preoperative anemia in fast-track TKA however has been seen to be associated with an increased risk of patients receiving transfusion during admission, increased risk of readmission within 90 days from the procedure and increased risk of LOS of more than 5 days [7].

To our knowledge, the effect of an implant design on overcoming these challenges has not been examined. Customized implants, designed to provide optimal fit by replicating patient individual knee geometry, and particularly, restoration of the patient’s femoral condylar anatomy, have been introduced to the market with the goal to achieve better patient outcome, faster recovery and mobilization post-surgery and therefore reducing the time of hospitalization.

Hence the purpose of our study was to compare standard off-the-shelf implants with a customized TKA design in a well-defined “Fast-Track” setting to determine, if implant design has any significant influence on hospital metrics or patient outcomes.

**Methods**

In this single-center case series sixty-two (62) patients were prospectively enrolled and were implanted with one of two implant systems. All surgeries were performed by the same surgeon. All patients consented for their data to be used for research purposes. Patients were given the option to choose between the customized and a standard off-the-shelf (OTS) implant based on the preference for timing of the surgery. Patients who preferred their procedure to be on the next possible date were treated with the OTS implant and patients who were willing to wait 6 weeks, the timespan needed for the implant manufacturing process, with the customized design.

This resulted in thirty (30) patients being treated with an OTS (53% female) (Columbus® Total Knee System, B Braun Melsungen AG, Hessen, Germany; Vanguard® Knee System, Zimmer Biomet, Warsaw, Indiana) and thirty-two (32) with the customized implant (41% female) (iTotal®G2, Cruciate Retaining TKA, ConforMIS, Inc., Billerica, MA). Regardless of component brand, all patients in both groups received a cruciate retaining TKA level of constraint. Patient demographics in terms of age at the time of surgery (57.2yrs OTS and 57.3yrs Customized; p=0.969), BMI (31.0 OTS and 33.4 Customized; p=0.116) and 17 tracked comorbid conditions (e.g. Diabetes, coronary artery disease, hypertension etc.) were collected preoperatively to ensure patients of both groups were comparable. No statically significant difference could be seen in the observation (Tables 1 and 2). During hospitalization the same institutional fast track protocol was utilized on all patients included in this study. As such it involved preoperative medical treatment with Hibiclens® (Mölnlycke, Norcross, Georgia, USA) daily for three days and Bactro-

<table>
<thead>
<tr>
<th>Table 1. Patient demographics</th>
<th>OTS</th>
<th>Customized</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>30</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Gender (% Female)</td>
<td>53%</td>
<td>41%</td>
<td>0.45</td>
</tr>
<tr>
<td>Body Mass Index (BMI)</td>
<td>31.0 (22-38)</td>
<td>33.4 (24-53)</td>
<td>0.116</td>
</tr>
<tr>
<td>Age at Surgery (Years)</td>
<td>57.2 (34-67)</td>
<td>57.3 (42-72)</td>
<td>0.969</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Patients comorbidities. Seventeen comorbidities were tracked pre-operatively but no significant differences were seen between the two groups</th>
<th>OTS</th>
<th>Customized</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic</td>
<td>5</td>
<td>6</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>CAD</td>
<td>0</td>
<td>2</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HTN</td>
<td>13</td>
<td>16</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>RA</td>
<td>2</td>
<td>2</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Smoker</td>
<td>5</td>
<td>6</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Contracture</td>
<td>2 &lt; 100</td>
<td>3 &lt; 100</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3. Medication flow chart of the fast-track protocol</th>
<th>One Week Before Surgery</th>
<th>At Surgery</th>
<th>Hospital / Home</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celebrex 200Mg</td>
<td>Marcaine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Minutes Before Celebrex 200Mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cymbalta 60Mg</td>
<td>Exparel 20Cc W/100CC of Saline</td>
<td>Norco 10/325 Prn</td>
<td></td>
</tr>
<tr>
<td>Norco T Prn</td>
<td>Spinal</td>
<td>Morphine/Dilaudid</td>
<td></td>
</tr>
<tr>
<td>Lowenox</td>
<td></td>
<td>Aspirin 325</td>
<td></td>
</tr>
<tr>
<td>Cymbalta 60Mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ban® nasal ointment (GlaxoSmithKlein, Brentford, London, UK) starting 48 hours prior surgery to remove potentially pathogenic bacteria from the nasopharyngeal region as well as patients ceasing all anticoagulants 5 days prior to the procedure. All study participants underwent an educational review consisting of a preparation course, a CD and a pamphlet to inform about the operational flow, possible complications and evaluating and setting patient’s expectations. A standard set of medications (Table 3) was given to all subjects participating in this study pre-, at and post-surgery. Post-operatively all patients were mobilized within 3 hours and were treated with CPM or Active Ice® 3.0 (Polar Products, Inc., Stow, OH, USA) if needed. As for criteria of discharge, patients had to be able to walk over 100 feet, get out of bed independently and needed to have at least 60° of flexion. Both, discharge criteria and the time of discharge was determined by physical therapist and hospitalist, independent of the surgeon.

During the data collection we assessed patient’s time of discharge, the total length of stay in the hospital (LOS) as well as their discharge destination. Patient’s range of motion (ROM) and the need for walking aids were examined at their 6-8 week post-op visit and at an average of 16 months post-op. All adverse events including manipulation under anesthesia (MUA) and revisions were followed up to a minimum of 25 months post-op (average 28 months).

Statistical analysis was performed in Minitab 17.1 (MiniTab Inc, PA-USA). All data was included for the analysis. Continuous variables were tested for normality prior to statistical comparisons. Variables with a normal distribution were compared using 2 tailed t-test assuming unequal variances. Non-normal variables were tested using Mann-Whitney test. Categorical variables were compared between the customized and OTS outcomes using frequency counts. Significance was determined using a Fisher Exact Test. A p value of 0.05 was used to determine a significant difference between the customized group and OTS group outcomes.

### Results

Overall, when utilizing the “Fast Track” protocol, LOS was decreased to 2.1 days versus 3.6 days, which was the average LOS after TKA for patients in our institution that did not undergo the fast track protocol.

The data analysis revealed that the average length of stay using standard OTS implant designs was found to be 2.7 days (range, 1-6 days) and 1.6 days (range, 1-6 days) when the customized TKA got implanted. This difference was found to be of statistical significance (p=0.004). Although the LOS range was seen to be the same, there was one patient in the customized group who was hospitalized for 6 days compared to 6 patients who received the OTS TKA.

We observed that significantly more patients treated with the customized implant were discharged from the hospital.
hospital within 24 hours post-surgery (66%) compared to patients from the OTS TKA group (30%) (Figure 1) (p=0.006). When assessing patients discharge destination a significantly higher proportion of patients discharged home was seen in the customized group (97%) compared to the OTS group (80%) (Figure 2) (p=0.05).

At the 6-8 week follow-up time point significantly less patients with a customized implant needed a walking aid (13%) compared to patients with an off-the-shelf implant (60%) (p=0.02). During that time period we found a difference in range of motion between both groups with patients who got an OTS TKA implanted (101°) experiencing 13% less ROM on average than patients with the patient specific implant (114°) (Figure 3).

Range of motion at an average of 16-month follow-up continued to be significantly higher among patients with the customized TKA (122° vs. 114° p<0.001). Additionally, a significantly higher proportion of patients with the customized TKA than patients with the standard TKA were found to have a ROM of ≥120° at the final time of follow-up (84% vs. 45%; p=0.003). None of the patient with the customized implant showed a ROM of <100° compared to 13% of patients with the OTS implant at the time of the final follow-up (Table 4). This was shown to be of statistical significance (p=0.046).

For adverse event reporting the average follow-up of the cohort was 28 months. Post-operatively there were two manipulations under anesthesia in the customized group and one among the OTS patients (p=0.99). There were no returns or re-admissions to hospital in a 60-day period. One patient in the customized group underwent a revision procedure at 30 months post op due to a fractured tibia resulting from a fall that loosened the tibial baseplate. In the OTS group there was 1 patient who developed a late infection at 2.5 years and had to be revised. In addition, one patient in the OTS group underwent a poly swap procedure to correct instability.

Discussion

Fast-track surgery has been implemented to improve surgical management by improving perioperative care and decreasing postoperative complications and therefore shorten the time of full recovery and reduce the need for hospitalization and convalescence. The “Fast-Track” program has been introduced by Kehlet et al and been developed and applied to clinical practice over the last 15 years [8, 9]. With the purpose of enhancing the cost-effectiveness and general efficiency of health care, multiple factors during patient’s time of hospitalization and their impact on patient’s recovery have been analyzed. Optimized pain management, transfusion strategy, rehabilitation and physiotherapy, patient’s information, fluid management and anaesthetic technique has led to a LOS of 1-2 days after TKA and better patient post-operative outcomes [4, 6, 10, 11].

To our knowledge the potential influence of the implant design on peri- and post-operative outcomes after TKA in a fast-track setting has not yet been described. We believe this is the first study to compare the effect of the knee implant design on length of stay and hospital metrics in a defined fast-track program. Our study was not without limitations which have to be taken into consideration when interpreting the results. This study was carried out prospectively with patients selecting the implant design. Including blind randomization of the patient / component matching may have eliminated potential selection bias between the two study groups. Therefore we had little influence on the composition of the study cohorts which might have led to inequalities between the study groups. However, since patient demographics and comorbid conditions were similar and no statistically significant difference was detected between the two groups we consider our result to be valid. With a total of 62 patients participated in this study our patient cohort was relatively small. Nevertheless, the dif-
ferences seen between the groups were large enough to be of significance and we believe they would be similar for a larger study population. We suggest that further research with a larger study population should be undertaken in the future. For this study all TKAs were performed by a single surgeon who is experienced with all devices used. Experience and a high expertise in performing TKA has been shown to result in better outcomes and additional studies at different sites should be conducted to verify if the implant design does have an impact on a faster discharge. Lastly, fast track surgery can be implemented in multiple ways with the same guidelines but different protocols. Our results only reflect the fast-track protocol we utilized in this study. As there is no single definition of the “fast track protocol” in literature we propound that our protocol should be used in future research in order to validate our findings.

Overall, we observed a reduction in length of stay of 0.4 days after implementing the fast track protocol (3.1 days to 2.7 days). However, when using the customized implant, the average length of stay was reduced by a further 1.1 days. Culler et al compared LOS after TKA of patients treated with a customized implant and patients treated with an OTS design and noticed a tendency of reduced LOS in the customized group. Additionally, they found that a significantly greater proportion of patients in the customized study arm were being discharged from their TKA hospitalization in <3 days (<72 hours from admission to discharge) than in the OTS arm [12]. We can therefore agree with and support their findings that patients treated with the customized implant experience shorter LOS than patients with the OTS design.

In a study to evaluate whether there is a significant difference in surgical time, intraoperative blood loss, post-operative range of motion and length of stay between customized and OTS TKA Schwarzkopf et al observed a decreased range of motion with customized compared to off-the-shelf implants [13]. When assessing postoperative ROM, we had different findings. Patients with the customized implant design showed significantly better results both, at 6-8 weeks after surgery and at an average of 16 months post-op, than patients treated with the OTS implant. As having more than 60° of flexion was a discharge criterion in our study we believe that providing better results in ROM early after surgery could be one reason for higher ROM of customized patients.

The number of patients being discharged to a rehab facility (SNFs) was significantly higher in the OTS study group than among the customized patients. Additionally, more patients in the customized group went home after their time of hospitalization than patients in the OTS group. Reasons for a discharge to rehab care facilities have been examined in previous research and found to be correlated to patient’s demographics and characteristics e.g. comorbid conditions [14-16]. As we observed no significant difference in those metrics between our study arms, we assume that the difference in the implant plays a crucial role in patient’s post-surgical recovery and therefore in their discharge destination.

In the light of the Comprehensive Care for Joint Replacement (CJR) program, bundled payments will be paid for TKA procedures based on multiple variables in order to improve healthcare costs and treatment efficiency. Previously published studies have revealed great cost variations for different discharge settings and potential savings due to shortened length of stay [17-19]. Utilizing discharge costs analysis as published by Ramos et al we observed a potential average cost reduction when using the customized implant for less patients being discharge to inpatient rehab facilities of $1,100 per patient. Furthermore, our results would potentially save hospitals $1,100 per patients on average from a shortened average length of stay of 1.1 days (LOS of 2.7 days in OTS group and 1.6 days in the customized group). In summary, based on our findings healthcare costs could be potentially cut by approximately $2200 by using the customized compared to OTS implants.

We believe that the customized implant has a positive influence on patient outcomes in a “Fast Track” setting and surgeons and hospitals should consider implant choice as an important factor in fast-track TKA surgery.

References


Restoration of Femoral Condylar Anatomy for Achieving Optimum Functional Expectations: Continuation of an Earlier Study At 5-Year Minimum Follow-Up

Durbhakula S 1, Durbhakula V 1, Durbhakula N 1

Abstract

Background: Studying and reporting the continuous, prospective outcomes of a post-surgical orthopaedic population without loss to follow-up at various standard landmarks over time is rarely achieved in total knee arthroplasty (TKA) literature. Small case series populations reported at an early follow-up time is common, and usually not beyond any initial publication for further reporting. The purpose of this study was to advance the knowledge base of the performance of Freedom Knee system through the continuous monitoring of a previously reported early series TKA patient population.

Methods: A prospective, continuous series of 176 primary posterior stabilized (PS) TKAs were performed in 172 patients by a single surgeon. Femoral component size distribution was assessed and all patients were followed for a minimum of five-years post-operatively. Total Hospital for Special Surgery (HSS) scores and range of motion (ROM) was assessed for the entire cohort and by gender.

Results: There were no patients lost to follow-up. Two patients required early post-operative incision and drainage for superficial wound infection of the indicated knees. One patient required tibial component and polyethylene insert revision following a motor vehicle accident resulting in a proximal tibial fracture and component loosening. There was no radiographic evidence of component failure. As expected, femoral component size frequency use was skewed by gender with the larger sizes in males. There were no pre- or post-operative clinical or functional differences by gender and at the recent follow-up (avg. 6.9 years). In addition, there was an average significant increase in change of HSS score (p<0.001) and ROM (P<0.001) when compared to pre-operative baseline but no significant difference in HSS or ROM between the two and five-year outcome results.

Conclusions: The design characteristic for component sizing and functional expectations were re-confirmed in the reported Western population cohort series, and observed optimum safety, performance and efficacy through five-years. Further continued study efforts of this primary TKA system is warranted across multiple surgeons and all ethnic cultures.

Background

Studying and reporting the continuous, prospective outcomes of a post-surgical orthopaedic population without loss to follow-up at various standard landmarks over time is rarely achieved in total knee arthroplasty (TKA) literature. [1,2] Small case series populations reported at an
early follow-up time is common, and usually not beyond any initial publication for further reporting. [3,4] Equally common is reporting the “average time to follow-up” across a large range of time post-operatively. [4,5] There exists a number of well known reasons for discontinuing review of an initial population including lack of interest due to removal of the original component offering, changes in component design, new competitive product offerings, change in surgeon / corporate alliance, and surgical practice growth reducing the ability to track all patients.

Of the few long-term continuous reports, the publication series on the cemented Total Condylar prosthesis (Johnson & Johnson, New Brunswick, NJ; Howmedica, Rutherford, NJ) spans 20 years, [1,6-8] and the Press-Fit Condylar (DePuy Orthopaedics, Warsaw, IN) has been reported through 25 years. [9] The authors have followed the long-term results of their respective original populations through various post-operative landmarks that yielded multiple intermediate publications. [10-14] In all, these study series have revealed successful “performance and reliability of a surgical procedure”, the long-term durability of the prosthetic composite and has set benchmarks by which other component series are studied and understanding on the longevity and outcome of these devices and patient population.

The design concept and early results of 176 MAXX Freedom Total Knee® system TKA patients, with a minimum follow-up at 2-years, have been previously published. [15] In an effort to advance the knowledge of the prospective results of the Freedom TKA system, the original patient population identified in the previously published study was monitored through their 5-year follow-up landmark. The purpose of this study was to advance the knowledge base of the performance of Freedom Knee system through the continuous monitoring of a previously reported early series TKA patient population.

**Materials and Methods**

As was previous reported at the two-year post-operative follow-up, between November 2010 and December 2013, the senior author performed 176 consecutive primary TKAs in 172 patients, without selection, utilizing the posterior stabilized (PS) Freedom Total Knee® system (MAXX Orthopedics, Inc., Norristown, Pennsylvania) (Figure 1). [15] The Freedom Total Knee system is manufactured from cast cobalt chromium (ASTM F-75 CoCr-Mo), and the articular bearing surfaces use ram-extruded UHMWPE (GUR 1020). The Freedom Total Knee system was also designed with the intent to address bone conser-
vation while permitting optimal high-flexion motion up to 155 degrees, dependent on the patient’s anatomy and cultural activities of daily living, such as frequent and prolonged squatting and kneeling. To achieve high-flexion, the femoral component was engineered utilizing a multi-radius design in which seven tangential radii were incorporated to accommodate changes in rollback across the available surface through the transition from walking through deep flexion (Figure 2). In addition, development of femoral component sizing was optimized to include the anthropomorphic dimensions of Western and Pan-Asian patient populations.

Of the 172 patients studied, there were 129 females (75.0%) and 43 males (25.0%) with an average patient age at surgery of 69.7 ±7.6 years (range: 52.3 years to 98.6 years). The average age of the female patient (69.3 years) when compared to the male patients (70.7 years) was not significantly different (p=0.311). (Table 1) In this continuous series, four female patients underwent bilateral TKA under the same anesthesia. In this set of patients, the pre-operative diagnosis was predominately degenerative joint disease (DJD) in 170 knees (96.6%) and rheumatoid arthritis (RA) in 6 knees (3.4%). The surgical side was evenly distributed across all patients with 86 left (48.9%) and 90 right (51.1%) knees (Table 1). In all cases the deep-vein thrombosis (DVT) prophylaxis was Lovenox® (Sanofi-Aventis, Bridgewater, NJ).

**Results**

All 172 originally studied patients had a post-operative minimum follow-up of 5-years with an average time to follow-up of 6.5 ±0.9 years (range: 5.0 years to 8.1 years). Overall, the pre-operative Hospital for Special Surgery (HSS) score was 49.2 ±5.7 (range: 40.0 to 65.0), which significantly improved to a 2-year follow-up average of 88.4 ±3.6 (range: 80.0 to 95.0) (p<0.001) and remained statistically identical a 5-year follow-up average of 88.8 ±3.4 (range: 80.0 to 95.0) (p<0.001 Table 2). As observed with the HSS at 2-years minimum follow-up, there was no statistical difference in pre-operative (p=0.208), 2-years post-operative (p=0.939), 5-years post-operative (p=0.366) or any difference between 2- and 5-years (p=0.505) by gender for HSS.

Functionally, the pre-operative range of motion (ROM) was 113.8 ±6.1 degrees (range: 95 degrees to 125 degrees), which significantly improved at the 2-year minimum follow-up ROM of 128.5 ±4.3 degrees (range: 110 degrees to 140 degrees) to an average 5-year post-operative ROM of 128.7 ±4.1 degrees (range: 115 degrees to 140 degrees). The change in ROM was statistically significant at p<0.001. There was no statistical difference in pre-operative (p=0.566), two-years (p=0.702) or five-years (p=0.913) in ROM by gender. All pre- and post-operative HSS and ROM data is summarized in Table 2. There was no radiographic evidence of aseptic component loosening or osteolysis (Figures 4A - 4C).

As was previously reported, two patients (1.1%) required subsequent incision and drainage surgery for superficial wound infections. Following these procedures both patients went on to successful clinical and functional outcomes through two and five-years post-operatively. No other patient had any subsequent infection through five-years. However, at 4.5-years post-index TKA, one female patient (<1%) with a previously well-functioning, Free-

---

**Table 1. Patient Demographics** - there was no statistical difference in patient age at p = 0.311. Also, there were 172 patients with 176 TKAs (4 bilateral cases).

<table>
<thead>
<tr>
<th>Total Patients</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>43 (25.0%)</td>
<td>129 (75.0%)</td>
</tr>
<tr>
<td>Average Age</td>
<td>70.7 ±7.3 years</td>
<td>69.3 ±7.7 years</td>
</tr>
<tr>
<td>Side</td>
<td>R = 21 (51.2%)</td>
<td>R = 86 (48.1%)</td>
</tr>
<tr>
<td></td>
<td>L = 22 (48.8%)</td>
<td>L = 67 (48.1%)</td>
</tr>
</tbody>
</table>

**Table 2. Independent of gender, changes in HSS and ROM from pre- to either post-operative follow-up landmarks were statistically significant (p < 0.001). There was no statistical difference in patient outcomes between genders at any landmark for pre-operative or post-operative HSS or ROM.**

<table>
<thead>
<tr>
<th>Total Population</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avg Follow-Up</td>
<td>6.5 ±0.9 years</td>
<td>6.3 ±1.1 years</td>
</tr>
<tr>
<td>HSS Score</td>
<td>49.2 ±5.7</td>
<td>48.3 ±5.6</td>
</tr>
<tr>
<td>Pre-Operative</td>
<td>88.4 ±3.6*</td>
<td>88.4 ±3.4*</td>
</tr>
<tr>
<td>2-Years Follow-Up</td>
<td>89.2 ±2.9*#</td>
<td>89.2 ±2.9*#</td>
</tr>
<tr>
<td>5-Years Follow-Up</td>
<td>114.3 ±6.0</td>
<td>114.3 ±6.0</td>
</tr>
<tr>
<td>Range of Motion</td>
<td>128.5 ±4.1*</td>
<td>128.5 ±4.3*</td>
</tr>
<tr>
<td>2-Years Follow-Up</td>
<td>128.6 ±3.7*#</td>
<td>128.6 ±3.7*#</td>
</tr>
<tr>
<td>5-Years Follow-Up</td>
<td>132.6 ±3.7*#</td>
<td>132.6 ±3.7*#</td>
</tr>
</tbody>
</table>

* Statistically significant difference from baseline at p < 0.001
# No statistical difference between 2-year and 5-year follow-up results
A total knee system prosthesis was involved in a motor-vehicle accident (MVA) that resulted in chronic pain and decrease of function involving the left proximal tibia. There was radiographic evidence of a proximal tibial stress fracture and tibial component loosening which were confirmed at the time of tibial component revision. Only the index tibial component and polyethylene insert were removed and a cemented MAXX Freedom® Knee Revision tibial baseplate (MAXX Orthopedics, Inc., Plymouth Meeting, Pennsylvania) with an extended tibial stem and PS polyethylene tibial insert were implanted without the use of any other adjunctive fixation hardware. The patient recovered without issue and at the most recent follow-up is well functioning without pain or ambulatory deficit.

**Discussion**

We report on the minimum five-year follow-up of a single surgeon, non-randomized, consecutive case series of patients that received the Freedom Total Knee system for primary TKA. This is the second prospective follow-up report of the original population previously published. [15] The results of this current follow-up show reveal continued optimum TKA performance without patient lost to follow-up, related complications, component failure or deterioration of the prosthetic composite.
Continuous monitoring of total joint arthroplasty devices is of paramount importance including review of new technologies, materials and material combinations, and clinical relevance. Within the current healthcare budgetary climate and increasing healthcare costs, hospital systems are requiring increasing levels of device claims proof prior to approval and use. Currently, while the United States Food and Drug Administration (FDA) is the primary regulator of public health safety involving drugs and devices, there is no centralized technology assessment organization for technology and device monitoring. Therefore, various societies and associations have developed multiple voluntary registries that are beginning to yield published observations. [16-18] Unlike the existing international joint arthroplasty registries that are mandatory for all cases performed, voluntary participation in US domestic registries introduces a bias in the devices referenced and data collected. Prospective continuous case series studies can be used to generate information to use for publication, presentation or various hospital Value Added Technology (VAT) committees. The strategic use of large continuous patient study series may yield information that is meaningful for assessing component performance over time. Serial publications of the Total Condylar knee replacement revealed early issues with femoral component sizing, instrumentation and evolving design considerations from the original single pegged cemented patella. [2,10,11,13] These items are of common knowledge today yet were not known upon the early design releases until tried and monitored. Intermediate studies have shown results for component design, patient morphology and surgical technique with and without navigation. [6,14,19-22] Our results have shown favorable restoration of femoral condylar anatomy and restoration of continuous normal knee function through two and five-years in the same study population.

From our patient monitoring efforts with this study we had one patient that required revision of the tibial component following an MVA 4.5 years post-operatively. At the time of revision surgery, use of the MAXX Freedom Knee Revision tibial component was used which allowed for retention of the well-fixed and functioning index primary femoral component. The MAXX Freedom Knee Revision tibial component is engineered to be bone conserving and allows for the use of the available MAXX modular polyethylene inserts independent of femoral component constraint. This avoided the risks that are associated with prolonged surgery that would have most likely occurred with any attempt to remove the well-fixed femoral component and reimplantation of an entire revision TKA system. In addition, the multiple straight or offset stem options are available dependent on the patient’s available tibial anatomy. In this specific case, a stem was required to bypass the proximal tibial fracture. There were no other patients presenting with clinical or radiographic evidence of adverse events or component failure.

As was identified in the earlier publication, this single surgeon, non-randomized consecutive case series had an imbalance of patients by gender (females n=129, males n=43). [15] However, other than femoral component size usage, the measured clinical outcomes were not statistically different when comparing by gender. In this population Lovenox® (Sanofi-Aventis, Bridgewater, NJ, USA) was used in all patients as their DVT prophylaxis, which has been changed to aspirin due to current results in the literature. Also, the patients included were of a Western ancestry population, so no comparative assessments to Middle-Eastern or Pan-Asian populations were available. However, efforts are being made to capture a similar study data across various ancestral populations for comparative review with the currently presented study group.

In conclusion, the reported study of patients receiving the Freedom Total Knee system for primary TKA support the design considerations for anthropomorphic considerations while achieving an increased degree of ROM while minimizing bone resection. The study included a large cohort (n=172) of continuous non-selected series of patients without loss to follow-up for any reason through 5-years. In a cooperative effort between the author and the company, every effort will be made to continue study of this study population through the next follow-up landmark. From these results we believe that continued use and study is warranted to confirm achieving similar results across surgeons and to further study multiple ancestral populations.

Acknowledgment

The authors wish to thank Robert Eberle for his assistance with the preparation of this manuscript.

References


Techniques of Insertion and Early Clinical Impressions with a Short Curved Tissue Sparing Implant for Total Hip Arthroplasty (The French Experience)

Venet G1, Tesson A2, Le Cour Grandmaison F1, Fraquet N1, Brazil D2, McTighe T3

Abstract

Background: Total hip arthroplasty (THA) is one of the most effective orthopedic procedures, providing consistently high success rates across all population segments as measured by pain relief, improved function, and patient satisfaction. However, clinical outcomes have been less favorable in young active patients, that lead to the re-development of metal on metal hip resurfacing (HR), with the most successful being the Birmingham Hip Replacement (BHR) introduced in 1997. Evolving complications due to increased metal ion debris has lead to a great reduction of use for all metal on metal (MOM) HR designs, leading many surgeons and patients to look for an alternative surgical selection. This search has focused on the development and use of short stems for THA. One such style of short stems is curved neck preserving designs. This paper will review our French experience with one of those designs.

Materials and Methods: This is a retrospective review of four surgeons series of a short curved tissue sparing cementless femoral implant (TSI™ Hip Stem, Signature Orthopaedics) for THA. The femoral component was used with two different cementless acetabular styles (Mathys RM Pressfit, and Zimmer Biomet Allofit®). Results on the cups will not be revived in this paper. 150 TSI™ Stems by four surgeons at the same institution utilizing the posterior surgical approach since September 2016. 40% women, average age 66 years with extremes of 27 to 78 years. 10 cases of dysplastic hips, 6 cases of aseptic osteonecrosis, 1 fracture, 1 rheumatoid coxitis, and the rest primary coxarthrosis, with 7 patients operated on both hips at the same time. 23.3 % have been Dorr type A canal shape.

Results: There has been no aseptic loosening, three femoral components have been explanted due to postoperative infection. There was one intra-operative femoral distal fracture in a Dorr type A bone profile during stem insertion. One posterior dislocation; there has been two patients with thigh pain with pathological bone scan, and one with low back pain and no leg length discrepancies greater than plus or minus 5 mm.

Conclusion: This short curved tissue sparing implant has demonstrated excellent initial short-term results, with excellent implant stability, excellent medial calcar bone remodeling with one dislocated stem, two thigh pain and one patient with low back pain. One distal intra-operative fracture in a Dorr type A bone. This has now been addressed with the use of distal sizing gauges and the use of flexible reamers to open the distal canal prior to stem insertion. Removal of the infected stems demonstrated implant stability.
with early bone attachment in the proximal porous surface. The high neck resection allows for ease of revision and conversion implanting a new primary conventional length cementless stem design.

There is a short but definitive learning curve in fitting the implant to the femoral neck versus the standard metaphyseal and diaphyseal conventional style stems.

**Background**

Total hip arthroplasty (THA) is one of the most effective orthopedic procedures, providing consistently high success rates across all population segments as measured by pain relief, improved function, and patient satisfaction. [1] However, clinical outcomes have been less favorable in young active patients, [2,3] which lead to the re-development of metal on metal hip resurfacing (HR), with the most successful being the Birmingham Hip Replacement (BHR) introduced in 1997. [4] Evolving complications due to increased metal ion debris has lead to a great reduction of use for all metal on metal (MOM) HR designs, leaving many surgeons and patients to look for an alternative surgical selection. [5,6,7]

In the past ten years short stems and in particularly neck preserving stem designs have received a significant level of interest at continuing medical education (CME) meetings as a result of the decline of HR. [8,9,10]

**Material and Methods**

This is a retrospective review of four surgeons series of a short curved tissue sparing cementless femoral implant (TSI™ Hip Stem, Signature Orthopaedics) for THA. The femoral component was used with two different cementless acetabular styles (Mathys RM Pressfit, and Zimmer Biomet Allofit®). Results on the cups will not be revived in this paper.

150 TSI™ Stems by four surgeons at the same institution utilizing the posterior surgical approach since September 2016. 40% women, average age 66 years with extremes of 27 to 78 years. 10 cases of dysplastic hips, 6 cases of aseptic osteonecrosis, 1 fracture, 1 rheumatoid coxitis, and the rest primary coxathosis, with 7 patients operated on both hips at the same time. 23.3 % have been Dorr type A canal shape. Figure 1.

The TSI™ stem (Tissue Sparing Implant) is a short, anatomically curved stem designed to retain most of the patient’s femoral neck. The implant sits in the patient’s femoral neck, and curves anatomically down into the patient’s proximal femoral canal, to maintain anatomical compressive loading of the retained bone. The stem is manufactured from Ti6Al4V alloy and is proximally coated with titanium plasma spray plus hydroxyapatite (HA) to promote bone attachment. The stem is distally polished and has a sagittal plane cutout to reduce distal hoop tension which has been shown to induce thigh pain [11]. Additionally, the stem has a gentle conical flare at the resection line to reduce subsidence and maintain compressive loads to the medial calcar. A lateral T back design enhances torsional stability reducing chances of aseptic loosening (Figures 2 & 3).

The simple yet novel short curved stem design reduces the need to go lateral into the trochanteric bed where you can increase damage to the musculature and cancellous bone resulting in increased blood loss. Six degrees of femoral neck anteversion is built into the TSI stem with one medial stem curve. Stem length and medial curve allow for more tissue preserving techniques for both soft and
hard tissue without sacrificing implant stability. The internal proximal conical flair provides for a unique structure to enhance proximal compressive load transfer to the medial calcar resulting in less medial calcar resorption.

**Technique Femoral Preparation.** The first step is pre-operative planning utilizing either plain radiographic templates or dedicated software. Both femoral neck resection and resection angle can be predetermined to ensure proper restoration of joint mechanics and stem position.

Preoperative templating is crucial to select the appropriate implant size and optimal neck shaft angle. Prosthetic templates show the implant in a true A/P projection (approximately 20 degrees of internal rotation) while radiographs of arthritic hips may or may not represent a true A/P of the proximal femur and diaphysis because of positioning error and/or limited range of motion. If the hip is externally rotated, a position commonly seen in osteoarthrosis, the femoral neck appears shorter and more vertical [11,12] (Figure 4).

Lack of proper offset leads to soft tissue laxity as well as increased risk of impingement and dislocation. Templating is challenging even under the most optimal x-ray conditions since the surgeon is using two-dimensional x-rays to assess a three-dimensional femoral head and neck. In the osteoarthritic patient the femoral head position tends to be in external rotation. Traditional radiographs taken with the foot perpendicular to the cassette underestimate offset due to the position of the femoral head with respect to the image beam. Studies have demonstrated as much as 7mm can be underestimated in femoral offset in preoperative templating, especially in patients whose arthritis fixes the femur in external rotation [11,12,13] (Figures 5, 6).

The patient is in a decubitus lateral position with bottom and pubic support. The incision (about 8-10cm) is located on the greater trochanter’s posterior part, centered at the top. The acetabular and external rotators approach is done just next to the greater trochanter and the intra-trochanteric line while dissecting the internal and external obturator muscle and the gastrocnemius muscles. Flexing the hip and the knee, associated with an internal hip adduction rotation allows hip dislocation. The psoas, and the quadratus femoris muscle are preserved.

Using the postero-lateral approach to the hip, the superior one-half of the short external rotators are released from the posterior greater trochanter down to the base of the femoral neck. The capsule is preserved with transverse incisions made at the acetabular rim and the base of the femoral neck. A longitudinal capsular incision is made in between. This creates anterior and posterior capsular flaps that can be repaired at closure. Once the hip is dislocated, the femoral neck is resected 5 to 10 mm below the subcapital junction with a fine-toothed saw (Figure 7). The neck cut is based upon preoperative and intraoperative templating to restore head center of rotation. The neck sparing stem design and instrumentation is based upon following the native medial curvature of the proximal femoral neck (Figure 8).
Neck resection angle is important in achieving optimal stem placement and proper biomechanical loading of compressive forces on the medial calcar. The use of a resection guide or trial stem as a cutting template is helpful ensuring the proper angle and level of neck resection (Figure 9). If the neck resection is too vertical the stem can be in valgus, if resection is too horizontal the stem can end up in varus.

Opening the femoral canal can be accomplished by a number of ways dependent on surgeon’s preference. A curved curette, a curved metal sucker, a trocar drill or our preference is the curved canal finder supplied in the set of instruments (Figure 10).

The femoral canal is then rasped with gentle force starting with the starter rasp with progression in sequence to the desired size fitting and filling the femoral neck. A canal sounder can be used to explore the distal size of the femur, and aid in determination of final stem sizing (Figures 11, 12).

A trial reduction can be performed with the rasp in place by using the appropriate trial neck and head or by the use of the trial stem with a modular neck and head (Figures 13, 14, 15).

Trial stem can be extracted and the final definitive stem inserted with gentle force. Over impaction can result in fracturing the femoral neck (Figures 16, 17).

Trial heads can be used on the final definitive stem to determine proper leg length and joint stability (Figures 18, 19).

Note: Neck-sparing stems are at increased risk for mechanical impingement, especially with retained osteophytes attached to the femoral neck. Head neck assessing for boney impingement tested at end flexion with internal rotation as well as at end extension with external rotation.

All impinging osteophytes and excess bone must be removed to maximize hip range without impingement and levering [14]. The use of head sizes of 32mm or greater is recommended. Acetabuli that require a 28 mm head or smaller may be better treated with a dual mobility style cup design.
Results

There have been three femoral components explanted due to postoperative infection (Figure 20). There was one intra-operative femoral distal fracture in a Dorr type A bone profile during stem insertion. There one posterior dislocation; there has been two patients with thigh pain and one associated with low back pain. One patient with purely mechanical pain was very intense initially but diminished with time (1 year post-op). Now she has little discomfort and little functional limitation. At the distal lateral portion of the stem there is a lateral cortical hypertrophy without a real pedestal. This can happen if the distal lateral portion of the stem engages or wedges into the isthmus of the femoral canal. Pain reduces as the distal bone stiffens around the implant. For this reason we aim for a neutral stem position within the canal (Figures 21, 22, 23). Note the medial conical flair is slightly proud of the resection line so there is diminished proximal load transfer as seen with some mild medial bone remodeling. No leg length discrepancies greater than plus or minus 5 mm. [14-15]

When the proximal conical flair is engaged with the medial calcar as seen in Figures 23, 24, and 25 the calcar is loaded in compressive forces and we see positive bone maintenance over the years. This is similar in radiographic results as seen and reported by van der Rijt at the European Hip Society and in 2012 Figure 26 with a similar neck sparing stem with a proximal conical flair. [16]
Conclusion

This short curved tissue sparing implant has demonstrated excellent initial short-term results, with excellent implant stability, excellent medial calcar bone remodeling with one dislocated stem, no aseptic loosening two thigh pain one patient associated with low back pain, one female patient that experienced anterolateral thigh pain at six months post-operatively with diminished pain at one year and one distal intra-operative fracture in a Dorr type A bone. This has now been addressed with the use of distal sizing gauges and the use of flexible reamers to open the distal canal prior to stem insertion. Removal of the infected stems demonstrated implant stability with early bone
attachment in the proximal porous surface. The high neck resection allows for ease of revision and conversion implanting a new primary conventional length cementless stem design.

There is a short but definitive learning curve in fitting the implant to the femoral neck as compared to implantation of a conventional style cementless stem. The neck resection is a critical part of maintaining positive medial calcar bone remodeling. Overall the authors are optimistic and continuing advocating the use of this neck preserving style stem.

References
7. Clarke I, Lazennec J. Margin-of-safety Algorithm Used with EOS Imaging to Interpret MHRA Warning for 46-48mm MOM Arthroplasty. https://doi.org/10.15438/rr.5.3.115

SUBMISSION HISTORY
Submitted: January 2, 2019
Reviewed: March 24, 2019
Accepted: March 26, 2019
Published: March 31, 2019

AUTHOR AFFILIATIONS
1 Guillaume Venet, MD; Antoine Tesson, MD; Francois Le Cour Grandmaison, MD; Nicolas Fraquet, MD
Service de Chirurgie Orthopédique et Traumatologique, CHD VENDEE, 89925 La Roche Sur Yon Cedex, FR
2 Declan Brazil, PhD
Signature Orthopaedics, 7 Sirius Rd Lane Cove West NSW 2066 AU
3 Timothy McTighe, Dr HS (hc)
Joint Implant Surgery & Research Foundation, 46 Chagrin Shopping Plaza, #117, Chagrin Falls, OH 44022 US
(Direct inquiries to Guillaume Venet, guillaume.venet@chd-vendee.fr)

AUTHOR DISCLOSURES
Guillaume Venet, Declan Brazil and Timothy McTighe declare Either family, institution I am associated with, or I have received benefits or funds either directly or indirectly regarding this article.
Drs. Tesson, Le Cour Grandmaison and Fraquet declare that there are no disclosures regarding the publication of this paper.

COPYRIGHT & OPEN ACCESS
© 2019 Venet, Tesson, Le Cour Grandmaison, Fraquet, Brazil, McTighe. All rights reserved. Authors retain copyright and grant the journal right of first publication with the work. Reconstructive Review is an open access publication and follows the Creative Commons Attribution-NonCommercial CC BY-NC. This license allows anyone to download works, build upon the material, and share them with others for non-commercial purposes as long as they credit the senior author, Reconstructive Review, and the Joint Implant Surgery & Research Foundation (JISRF). An example credit would be: “Courtesy of (senior author’s name), Reconstructive Review, JISRF, Chagrin Falls, Ohio”.
Irrisept’s bottle design allows users to control the pressure of the solution through manual bottle compression. The mechanical action of Irrisept helps remove bacteria, particulate and debris in wounds without harming underlying tissues.

Irrisept is a FDA-Cleared (K080779), Class II Medical Device

www.irrisept.com
Can We Improve Screening Costs in Asymptomatic Metal on Metal Total Hip Arthroplasties?

Martin JR¹, Otero JE², Springer BD¹, Griffin WL¹

Abstract

Background: Metal on Metal (MoM) total hip arthroplasty (THA) has been largely abandoned in the United States secondary to high failure rates. Many of the failures are attributed to adverse local tissue reactions (ALTR). Therefore, patients that have a MoM THA are routinely screened by checking serum metal ion levels every two years, as was recommended by the FDA. However, there is limited data on the costs of current screening protocols.

Materials and Methods: 318 consecutive patients who underwent a MoM THA at a single institution were retrospectively enrolled. The average follow-up was 8.2 years. Clinical data, metal ion levels, revision and reoperation rates were prospectively collected. The costs of clinical screening for this patient population was calculated and compared to the cost of an annual screening protocol.

Results: 12 patients had either an elevated Co or Cr level (>4.5 ppb). Eight patients were revised secondary to ALTR. The total cost of screening during the study was $612,250. Additionally, if annual screening had been performed, total screening costs would be approximately $1,719,200.

Discussion: Eight patients in the following study were revised secondary to ALTR with a total cost of screening of $612,250. These costs are substantially less than the cost of annual screening ($1,719,200). Due to the considerable costs of screening asymptomatic MoM THA patients, we recommend both optimizing the frequency of screening and evaluating the specific risk of the implant being screened.

Background

Metal on metal (MoM) total hip arthroplasty (THA) has largely been abandoned as a bearing surface as numerous studies have demonstrated adverse local tissue reactions secondary to the implant bearing [1–4]. The exact number of patients implanted with a MoM THA has been estimated to be over 1,000,000. It is believed that there remain hundreds of thousands of asymptomatic patients with these implants that still require follow-up. There is currently no consensus on how to screen this patient population to avoid complications associated with adverse local tissue reaction [5,6]. Some international screening protocols require annual follow-up with serum or whole blood cobalt and chromium metal ion levels. “Elevated” levels (which may range from 4.5 to 7.5 ppb) commonly require cross sectional imaging including a Metal Artifact Reduction Sequence Magnetic Resonance Imaging (MARS MRI) or an ultrasound [7–9].

Metal ion values have not demonstrated a clear relation-

Keywords: metal on metal; total hip replacements; screening protocols; cost savings
Level of Evidence: AAOS Therapeutic Level IV
ship in the diagnosis of adverse local tissue reaction [10]. The actual metal ion value that is considered “elevated” varies, and may not directly correlate with adverse local tissue reaction [11,12]. Additionally, the timing for obtaining metal ion levels and the time interval between screenings is not uniform. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) currently recommends annual screening for all patients with a MoM THA with a femoral head 36 mm or larger [13]. However, Kiran et. al. noted that metal ion levels remained stable after seven years and had no significant elevation. Therefore, they suggested that annual screening may not be necessary [12]. Additionally, there is a paucity of data available on the costs of screening this patient population.

Beginning in 2010, we adopted a protocol of monitoring metal ion levels every two years in asymptomatic MoM THA patients. Prior to this, routine screening was not utilized for asymptomatic patients. Revision THA secondary to adverse local tissue reaction has been minimal at our institution; therefore, there remains a substantial cost for screening this asymptomatic patient population. Consequently, the following study was designed to determine the costs of our current surveillance program on asymptomatic MoM THA patients and to compare these with the potential costs of annual screening. Additionally, we sought to determine the cost per patient to identify a single case of an adverse local tissue reaction.

Materials and Methods

After obtaining institutional review board approval, the following study was performed retrospectively. 318 consecutive patients underwent primary THA. All THAs were performed by the senior author, a fellowship trained arthroplasty surgeon, through a posterior approach. A Pinnacle (DePuy; Warsaw, IN) acetabular component with an Ultamet metal liner was utilized in each case. 98% of cases were performed with the S-ROM stem (DePuy; Warsaw, IN) and 2% were performed with an AML stem (DePuy; Warsaw, IN).

Patient Demographics

The patient cohort included 318 patients with 457 MoM THAs identified. The average age at the time of surgery was 55 years (20-78 years). The average time in situ was 8.2 yrs. The median femoral head size was 36 mm and the median cup angle was 40 degrees.

Screening Protocol

Routine monitoring for patients with asymptomatic MoM THA included a physical examination, AP pelvis and lateral radiograph of the involved hip, and cobalt and chromium metal ion levels. However, there was not a standardized time between physical examination/screens. Starting in 2010, patients were routinely screened every two years. The screening period coincided with the widespread availability of cobalt and chromium metal ion labs. Prior to this time, only a few centers had the ability to measure serum/whole blood metal ion levels. Sidaginamale et. al. [15] previously noted that a Co level of 4.5 ppb was highly sensitive and specific for the detection of abnormal wear of a MoM THA. While other cutoff values have been evaluated, we chose 4.5 ppb as a more sensitive screening level. Therefore, any metal ion level over 4.5 ppb was considered elevated by the senior author and the patient was then scheduled to undergo a MARS MRI. Fluid collections suggestive of adverse local tissue reaction in the setting of elevated metal ions were considered to be diagnostic for a failed metal on metal total hip arthroplasty and were subsequently revised. Therefore, we calculated the costs of screening based on 1) actual follow-up, 2) desired follow-up (every 2-years), 3) annual follow-up, and 4) every four-years with the assumption that the same number of ALTR were identified in each screening protocol. A multivariate analysis was performed on our patient population to determine if any patient demographics were associated with an increased risk of ALTR.

Costs of Screening

Costs of screening metal ion levels are not uniform and have changed throughout the duration of the study. The costs as of 2014 were approximately $300, but have decreased to around $124 as of 2018 for one laboratory. It should be noted that screening evaluations will likely continue to become more cost-effective with decreasing lab costs. However, in order to simplify the calculations, the costs of each screening modality are approximated. The table below demonstrates the approximate costs for each exam/test (Table 1).

<table>
<thead>
<tr>
<th>Exam/Test</th>
<th>Cost of Exam (dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Exam/X-rays</td>
<td>350</td>
</tr>
<tr>
<td>Metal Ion Levels</td>
<td>300</td>
</tr>
<tr>
<td>MARS MRI</td>
<td>2000</td>
</tr>
</tbody>
</table>

Patients were followed with serial clinical examination, x-rays, and metal ion levels. If an elevated metal ion level was identified, the patient underwent a MARS MRI. All patients that had a positive MRI (large fluid collections, soft tissue masses, etc.) and a clinical examination...
concerning for mechanical symptoms or increasing pain underwent revision for ALTR. The total costs of routine screening as well as MRI evaluation for those with elevated metal ion levels were calculated for this patient population. Additionally, the theoretical screening costs were then calculated utilizing both planned screening as well as annual serial screening protocols. It was assumed that the same number of elevated metal ion levels would be identified as well as the same number of ALTR.

**Results**

We identified 18 elevated cobalt and or chromium levels in 12 patients of the 318 (3.8%). The median cobalt and chromium level on lab draw one was 1.3 ppb and 1.1 ppb and on lab draw 2 was 1.4 ppb and 1.3 ppb, respectively. Of the 12 patients that underwent MARS MRI for elevated metal ion levels, eight patients (2.5%) had confirmed cases of ALTR and were subsequently revised. Of these eight patients, two had groin pain concerning for an ALTR, one patient had radiating low back pain, and the other five patients were minimally symptomatic. The only risk factor associated with ALTR was the time in situ (p=0.0008). Age, gender, cup abduction angle, and femoral head size were not statistically associated with an increased risk of ALTR.

**Total Cost of Current Screening**

The costs for the clinical evaluations and x-rays for this cohort was $316,750. The cost of screening patients with metal ion levels was $271,500. The costs of the MARS MRIs on 12 patients were approximately $24,000. Therefore, the total cost of screening for this study was $612,250 (Table 2). The cost therefore was $1,925 per patient.

<table>
<thead>
<tr>
<th>Exam/Test</th>
<th>Number of Exams (n)</th>
<th>Cost per exam (dollars)</th>
<th>Total cost (dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Exam/X-rays</td>
<td>905</td>
<td>350</td>
<td>316,750</td>
</tr>
<tr>
<td>Metal Ion Levels</td>
<td>905</td>
<td>300</td>
<td>271,500</td>
</tr>
<tr>
<td>MARS MRI</td>
<td>12</td>
<td>2000</td>
<td>24,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>612,250</strong></td>
</tr>
</tbody>
</table>

**Cost per ALTR**

Eight patients in this study were revised secondary to an ALTR which was confirmed on the pre-operative MARS MRI and intraoperatively. Therefore, our current screening protocol has a cost of $76,531 per ALTR identified.

**Costs of Planned Screening Protocol (every two years)**

Utilizing the planned screening protocol every two years, the cost of clinical exams and x-rays would be $456,750. The cost of screening the entire cohort of patients with metal ion levels would be $391,200. The costs of the MRI evaluations would also be $24,000. The total costs of screening utilizing this protocol would be $871,950, or $2,742 per patient. Additionally, the cost of this theoretical screening protocol would be approximately $108,994 per ALTR (Table 3).

<table>
<thead>
<tr>
<th>Exam/Test</th>
<th>Number of Exams (n)</th>
<th>Cost per exam (dollars)</th>
<th>Total cost (dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Exam/X-rays</td>
<td>1304</td>
<td>350</td>
<td>456,750</td>
</tr>
<tr>
<td>Metal Ion Levels</td>
<td>1304</td>
<td>300</td>
<td>391,200</td>
</tr>
<tr>
<td>MARS MRI</td>
<td>12</td>
<td>2000</td>
<td>24,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>871,950</strong></td>
</tr>
</tbody>
</table>

**Costs of Theoretical Screening Protocol (annual)**

Utilizing an annual screening protocol, the cost of clinical exams and x-rays would be $912,800. The cost of screening the entire cohort of patients with metal ion levels would be $782,400. The costs of the MRI evaluations would also be $24,000. The total costs of screening utilizing this protocol would be $1,719,200, or $5,406 per patient. Additionally, the cost of this theoretical screening protocol would be approximately $214,900 per ALTR (Table 4).

<table>
<thead>
<tr>
<th>Exam/Test</th>
<th>Number of Exams (n)</th>
<th>Cost per exam (dollars)</th>
<th>Total cost (dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Exam/X-rays</td>
<td>2608</td>
<td>350</td>
<td>912,800</td>
</tr>
<tr>
<td>Metal Ion Levels</td>
<td>2608</td>
<td>300</td>
<td>782,400</td>
</tr>
<tr>
<td>MARS MRI</td>
<td>12</td>
<td>2000</td>
<td>24,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>1,719,200</strong></td>
</tr>
</tbody>
</table>

**Comparison of Theoretical Screening Protocol (four-years)**

Utilizing a protocol to screen every four-years, the cost of clinical exams and x-rays would be $228,200. The cost of screening the entire cohort of patients with metal ion levels would be $195,600. The costs of the MRI evaluations would also be $24,000. The total costs of screening utilizing this protocol would be $447,800, or $1,408 per patient. Additionally, the cost of this theoretical screening protocol would be approximately $56,276 per ALTR (Table 4).
protocol would be approximately $55,975 per ALTR (Table 5). The following table compares the screening costs amongst the various durations of screening (Table 6).

**Table 5**

<table>
<thead>
<tr>
<th>Exam/Test</th>
<th>Number of Exams (n)</th>
<th>Cost per exam (dollars)</th>
<th>Total cost (dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Exam/ X-rays</td>
<td>652</td>
<td>350</td>
<td>228,200</td>
</tr>
<tr>
<td>Metal Ion Levels</td>
<td>652</td>
<td>300</td>
<td>195,600</td>
</tr>
<tr>
<td>MARS MRI</td>
<td>12</td>
<td>2000</td>
<td>24,000</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>447,800</td>
</tr>
</tbody>
</table>

**Table 6**

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Current Screening</th>
<th>Annual Two-years</th>
<th>Four-years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Costs (dollars)</td>
<td>612,250</td>
<td>1,719,200</td>
<td>447,800</td>
</tr>
<tr>
<td>Costs/Patient (dollars)</td>
<td>1,925</td>
<td>5,406</td>
<td>1,408</td>
</tr>
<tr>
<td>Costs/100 Patients (dollars)</td>
<td>192,500</td>
<td>540,600</td>
<td>140,800</td>
</tr>
</tbody>
</table>

**Discussion**

Current screening protocols for monitoring patients with metal on metal total hip arthroplasties are not uniform [14,16–18]. In the United Kingdom, annual screenings with metal ion levels are required. However, in the United States, starting in 2010 the FDA mandated ion level screening every two years for asymptomatic MoM THA. This mandate is no longer required but is still generally followed. One recent study has demonstrated that metal ion levels appear to remain stable over time and annual metal ion levels are likely not necessary [14]. This led us to re-evaluate our current screening process. There is a substantial cost for screening patients, and more frequent screens will continue to increase costs. However, to our knowledge, no study has evaluated the costs of screening protocols in asymptomatic patients with MoM THA. Therefore, the following study was designed to evaluate theoretical and actual costs of screening this patient population.

Utilizing a less stringent screening protocol than what the MHRA recommends in the UK (screening every year), we identified a total cost of screening for this study of $612,250 over an 8.2 year time period. These screening costs are relatively high. However, these costs are substantially less than what may be observed with annual screening protocols. Our results demonstrate an approximately three-fold increase in the costs of screening utilizing annual protocols. As was previously discussed and demonstrated in our study, metal ion levels appear to remain fairly constant with repeat lab evaluation [14]. It should be noted that the true incidence of ALTR was not known in our study. We have made the assumption that all cases of ALTR were identified with the current screening protocol. While it is intuitive that more frequent screening would lead to increasing costs, it is not certain if more frequent screening will identify more patients with an ALTR. MARS MRI has been noted to identify fluid collections in well-functioning ceramic on polyethylene and metal on polyethylene THAs [19,20]. The two main screening tools for identifying an ALTR (metal ion levels and MARS MRI) do not necessarily confirm the diagnosis of ALTR. Therefore, there does not appear to be a nonsurgical method for defining the true incidence of ALTR.

As was demonstrated in this study, screening asymptomatic MoM THA patients is expensive. Further research is necessary to more accurately define at risk patients for an ALTR. In this study, all patients were implanted with the Pinnacle MoM acetabular component. This implant has been associated with statistically significantly lower metal ion levels than other MoM implant designs [21]. Smith et. al noted the Median Co levels were 2.8 and 3.3 μg/l in the Durom and Birmingham groups, respectively, compared to only 0.52 μg/l in the Pinnacle group (p < 0.001). They also noted that the median Cr levels were 2 and 2.2 μg/l in the Durom and Birmingham groups, respectively, compared to only 1.2 μg/l in the Pinnacle group (p < 0.001). Only eight patients (<3%) had confirmed cases of ALTR in our study. It is possible that implant specific screening may result in increased efficiency of identifying ALTR as well as decreasing the costs of screening. Matharu et. al previously identified implant specific metal ion thresholds for detecting ALTR. This study evaluated the BHR and the Pinnacle modular two piece acetabular component [22]. These implant specific cutoff values were then applied to an external cohort of patients and were once again noted to improve the detection of an ALTR [23]. However, there remains debate as to whether or not there are truly implant specific differences in metal ion levels [23]. Therefore, future screening protocols may place an emphasis on the frequency of screening based on risk stratification [24]. Future screening protocols might include implant design, abduction angle, head size, and symptoms.

It should be noted that screening tests in the medical field are regularly utilized in order to identify conditions with a high morbidity and or mortality such as cancer. Screening tests are commonly highly sensitive and will be associated with few false negative results. However, these
tests may not necessarily be specific and often times require a confirmatory test to rule in or out the disease process. An example of this would be the prostate specific antigen (PSA) which is obtained to screen for prostate cancer. An elevated PSA (>4.0 ng/mL) will require a biopsy to confirm the diagnosis. Ideal screening tests are highly sensitive and have a low cost, and in the case of prostate cancer, the frequency and threshold of screening has been improved over time. Although an ALTR is not cancer, the associated morbidity can be devastating. For this reason, we still advocate screening asymptomatic patients with MoM THA. However, it is important to consider the costs of screening and potentially optimize the screening protocols to maximize sensitivity and decrease costs.

While the data was prospectively collected, the study design was retrospectively performed (retrospectively analyzing metal ions in a prospective cohort of MoM THA patients) and therefore has limitations. First, the screening protocol utilized in this study was not standardized. Serial clinical examinations, radiographs, and metal ion levels are now obtained every two years. During the majority of the study, routine screening protocols were not utilized. There is recent data that shows that serial metal ion levels may not be necessary in this asymptomatic patient population. Second, there are several limitations in the calculation of annual screening costs. It is possible that metal ion levels fluctuate day to day, or with activity, and therefore more frequent screening may increase the number of elevated metal ion levels obtained and potentially more ALTR identified. This has been simplified only to demonstrate the substantial cost differences noted when more frequent screening protocols are utilized. Third, metal ion labs have continued to decrease in costs. In 2014, cobalt and chromium ion levels cost approximately $300, however current costs have dropped to $124. Clearly, the cost-effectiveness will improve with decreasing costs of the test. Finally, the true incidence of ALTR is not known for the patient population in this study. Eight patients were revised with confirmed intraoperative ALTR identified. Only 12 patients underwent a MARS MRI and therefore 306 patients were not imaged. It is possible that a subset of these patients may have an ALTR with normal metal ion levels and therefore we note this as a limitation.

Conclusion

ALTR is a potentially devastating complication associated with MoM THA. Unfortunately, screening protocols are not uniform and rates of ALTR are low. The costs of screening asymptomatic patients in this study were $612,250. Due to the low incidence of ALTR in this patient population (n=8), the cost of screening per ALTR was $76,531. While more frequent screening may potentially increase the identification of ALTR, annual screening was associated with approximately a three-fold increase in the costs. Screening asymptomatic patients with MoM THA is necessary, but an emphasis should be placed on increasing the sensitivity of screening while decreasing the costs.

Bibliography


SUBMISSION HISTORY
Submitted: October 24, 2018
Reviewed: December 10, 2018
Revised: December 16, 2018
Accepted: March 8, 2019
Published: March 31, 2019

AUTHOR AFFILIATIONS
1 J. Ryan Martin, MD; Bryan Springer, MD; William Griffin, MD
OrthoCarolina, Hip and Knee Center, 2001 Vail Avenue Suite 200A, Charlotte, NC 28207
2 Jesse Otero, MD, PhD
University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242-1009
(Direct inquiries to Ryan Martin, johrmart@gmail.com)

AUTHOR DISCLOSURES
The authors declare that there are no disclosures regarding the publication of this paper.

COPYRIGHT & OPEN ACCESS
© 2019 Martin, Otero, Springer, Griffin. All rights reserved.
Authors retain copyright and grant the journal right of first publication with the work. Reconstructive Review is an open access publication and follows the Creative Commons Attribution-NonCommercial CC BY-NC. This license allows anyone to download works, build upon the material, and share them with others for non-commercial purposes as long as they credit the senior author, Reconstructive Review, and the Joint Implant Surgery & Research Foundation (JISRF). An example credit would be: “Courtesy of (senior author’s name), Reconstructive Review, JISRF, Chagrin Falls, Ohio.”

Charles Bechtol, MD
was internationally known in the fields of biomechanics and orthopedic surgery. His engineering and biomechanical research resulted in the development of numerous joint replacement implants and internal fracture fixation devices – instruments that are familiar to orthopedic surgeons the world over. His innovations included shoulder and knee prostheses, the Bechtol Total Hip system, the Bechtol “fluted” bone screw, and the Bechtol “continuous strength” bone plate.

Visit www.jisrf.org for more information.
What is Considered a Conflict of Interest or What to Disclose in Lectures and Publications?

McTighe T

Recently our Journal was criticized for allowing a co-author to submit and publish a technical paper when said surgeon is involved in a litigation matter. “I am very surprised indeed that you do not consider being a defendant in legal action concerning the very practice being defended in an article amounts to a conflict of interest.”

This made me think it might be an appropriate time to revisit this issue. I think it is important to understand some of the history regarding disclosure and conflict of interest.

What should a conflict of interest policy include when it comes to Continuing Medical Education (CME)? One might think this is an easy question but I have been involved with this question since the 1990s and find that it is one of the more difficult areas of debate. [1]

A policy on conflict of interest (COI) should require those with a conflict (or who think they may have a conflict) to disclose the conflict or potential conflict.

CME in the United States clearly dates back to the formation of the American Medical Association (AMA) in 1873 with publication of its first publication in 1883 Journal of the American Medical Association (JAMA).

This issue of COI has been much discussed and debated over the years and the topic of FDA investigation back in 1991 and 1992 resulting in a 1995 publication The Statutory Basis for FDA Regulation of Scientific and Educational Information. [2]

The Accreditation Council for Continuing Medical Education (ACCME) intervened in 1992 and was successful in pointing out to the FDA that a governing body was already in place concerning CME activities. However, the FDA did instruct the ACCME that if they changed their guidelines concerning commercial support of CME activities to standards they would basically back off from official involvement. As a result ACCME in 1992 adopted new standards for all ACCME accredited sponsors.

These 1992 standards have been the foundation for many organizations in establishing their own guidelines and standards for educational activities into publications. The ACCME has updated their Standards in 2004, 2005 and more recently in 2014. [3]

1992 ACCME Standards
1. General Responsibilities of Accredited Sponsors – The accredited sponsors are responsible for the content, quality, and scientific integrity of all CME activities certified for credit. Identification of continuing medical education needs, determination of educational objectives, and selection of content, faculty, educational methods and materials is the responsibility of the accredited sponsor. Similarly, evaluation must be designed and performed by the accredited sponsor.

2. Enduring Materials – The accredited sponsors are responsible for the quality, content, and use of enduring materials for purposes of CME credit.

3. Identifying Products, Reporting on Research and...
Discussing Un-Labeled Use of Products – Presentations must give a balanced view of options. Faculty use of generic names will contribute to the impartiality. If trade names are used, those of several companies should be used rather than only that of a single supporting company. Reporting scientific research offered by a commercial entity to provide a presentation reporting the results of scientific research shall be accompanied by a detailed outline in the presentation, which shall be used by the accredited sponsor to confirm the scientific objectivity of the presentation. Concerning unlabeled uses of products or an investigational use not yet approved for any purpose is discussed during the educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

4. Exhibits and Other Commercial Activities – When commercial exhibits are part of the overall program, arrangements for these should not influence planning or interfere with presentation of CME activities. Exhibit placement should not be a condition of support for CME activity. No commercial, promotional material shall be displayed or distributed in the same room immediately before, during, or immediately after an educational activity certified for credit. Representatives of commercial supporters may attend an educational activity but not engage in sales activities while in the room where the activity takes place.

5. Management of Funds from Commercial Sources – The ultimate decision regarding funding arrangements for CME activities must be the responsibility of the accredited sponsor. Funds from a commercial source should be in the form of an educational grant made payable to the accredited sponsor for the support of programming. The terms, conditions, and purposes of such grants must be documented by a single agreement between the commercial supporter and the accredited sponsor. No other funds from a chimerical source shall be paid to the director of the selectivity. Payment of reasonable honoraria and reimbursement of out of pocket expenses for faculty is customary and proper. Commercial support must be acknowledged in printed announcements and brochures. However, reference must not be made to specific products.

6. Commercially Supported Social Event – Should not compete with nor take precedence over the educational events.

7. Policy On Disclosure of Faculty and Sponsor Relationships – An accredited sponsor shall have a policy disclosure of the existence of any significant financial interest or other relationship a faculty member or a sponsor has with the manufacturer of any commercial products discussed in an educational presentation.

8. Financial Support for Participants in Educational Activities – In connection with an educational activity offered by an accredited sponsor, the sponsor may not use funds originating from a commercial source to pay travel, lodging, registration fees, honoraria, or personal expenses for non-faculty attendees. Scholarships or other special funding to permit medical Students, residents, or fellows to attend selected educational conferences may be provided as long as the selection of students, residents or fellows who will receive the funds is made either by the academic or training institution or by the accredited sponsor with the full concurrence of the academic or training institution.

Conclusion: There is no question that commercial support can contribute significantly to the quality of CME activities. However, there have been abuses in the past and the ACCME new standards will help to assure scientific integrity of all CME activities that receive certification for credit.

The standards have evolved and I would suggest anyone that publishes and or lectures at CME activities should know the Standards because most lectures that I have observed do not comply with the requirements.

In my opinion, although medical journals have lagged behind ACCME standards with regards to conflict of interest, they have established their own policies on the matter. Almost all medical journals now require authors to disclose COI, however the same standards have not been employed for editors and reviewers. [4] Haque et al, looked at 703 editors and COI policies at 60 medical journals. 57% of the journals had policies in place governing COI for editors, but only 21% publicly reported the disclosures. [4]

Journals and CME activities have focused on financial conflict of interest (FCOI) but is that sufficient? Certainly there can be other factors that can influence the behavior and actions of persons in a position of authority. A 2004 study, argued that “…the automatic nature of self-interest gives it a primal power to influence judgment and makes it difficult for people to understand its influence on their judgment, let alone eradicate its influence.” [5]

There have been published examples of overtly biased actions by editors. “For example, an orthopedic surgeon, during his tenure as an editor published many studies in his journal favoring products from a company, which paid him millions of dollars in patent royalties.” [6]

What about the potential issues of editors and or reviewers trying to gain favor by approving manuscripts submitted by key surgeons who influence appointments to key memberships in professional societies and committees. I suggest that we have to understand better what motivates behavior and what is the level of trust in a given profes-
What is Considered a Conflict of Interest or What to Disclose in Lectures and Publications?

In 2007 The American Academy of Orthopaedic Surgeons (AAOS) adopted Standards of Professionalism on Orthopaedic-Industry Conflicts of Interest that require orthopaedic surgeon members to identify and disclose potential conflicts of interest to their patients. [7]

JISRF created a web page that deals with Patient-Physician Guide, Patient Disclosure Letter, Patient Disclosure Poster, and AAOS Patient-Physician Communications. This page is not intended to be and end all result on the subject but a convenient resource page. We recommend that you also check with your individual professional societies for their policies on disclosure. [8]

All Policy and Procedures can be Viewed on Reconstructive Review Website. [9]

The following highlights some of our policies that pertain to COI.

The process of peer review assures the quality of the content in the articles, with the goal being new knowledge and skills that are of practical benefit to the readers of Reconstructive Review. The Editor-in-Chief and Managing Editor initially review all submissions. At this point articles may be rejected without peer review if it is felt that they are not of high enough quality or not relevant to Reconstructive Review. Once submissions pass initial review they are sent out for peer review.

To provide open-access, peer reviewed articles Reconstructive Review relies on individuals who are willing to take on the responsibility, and privilege, to review articles written by their peers. Please take a moment to look at the general guidelines we provide to reviewers that outline their purpose, good practices, and responsibilities.

Double-blind Review Process and Timeframe

Reconstructive Review operates a double-blind peer-review system; that is, reviewers and authors are not informed of each other’s identities during the review process. If the reviewer, Managing Editor, and/or Editor-in-Chief feel more revisions are deemed necessary a submission may undergo several reviews.

- Reviewers must take care not to identify themselves, their patients, or their institutions within the body of their comments.
- Reviews are read by the assigned Managing Editor, who makes the preliminary decision to accept or decline, or to ask the author to revise the article. The Managing Editor may also request that the reviewer comment on an extensively revised article that he or she had reviewed previously in an earlier version.
- Reviews are to be returned in a timely manner, within 2 weeks of invitation, as determined by the Editorial Board of Directors. Because the Managing Editor’s decision must wait until all reviews are complete, a delay by a single reviewer slows the editorial process. Reviewers agree to review an article only if they have the proper expertise and are confident that they can meet the deadline.

Based on the feedback from these reviewers and the judgment of the editorial team, a decision is given on the article. Possible decisions are to Accept Submission, Revisions Required, Resubmit for Review, and Decline Submission.

Once an article has been published in Reconstructive Review any ongoing, or post-publication review and/or commentaries are handled by submitting Letters to the Editor.

Appeals

If you believe the editorial team has incorrectly rejected your article, authors may send an appeal to the editorial office. To submit an appeal please send an email to the editorial office giving as much detail as possible about why you believe that your article has been incorrectly rejected. Please do not re-submit your article.

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Archiving

This journal utilizes the PKP Private LOCKSS network and Portico to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration. For more information please visit PKP Private LOCKSS network and Portico.

All content published on Reconstructive Review is digitally archived off site as well. When issues are created copies of full text articles are deposited on CrossRef. In addition, full backups are regularly performed by the site’s hosting company and by Journal Editorial Services.

Self-archiving

Under the terms of the license, authors are entitled to deposit the final published version of their article in institutional and/or centrally organized repositories immediately upon publication, provided that Reconstructive Review is attributed as the original place of publication and that correct citation details are given. Authors are also strongly en-
couraged to deposit the URL of their published article, in addition to the PDF version.

**Publication Ethics**

Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines. Reconstructive Review is currently registered with CrossRef and will be using their CrossCheck services to screen for plagiarism.

**Authorship**

All authors listed on the article should have contributed significantly to the experimental design, its implementation, or analysis and interpretation of the data. All authors should have been involved in the writing of the article at draft and any revision stages and should have read and approved the final version. Anyone who made major contributions to the writing of the article should be listed as an author (e.g. “ghost writing” is prohibited by Reconstructive Review). Any other individuals who made less substantive contributions to the experiment or the writing of the article should be listed in the acknowledgement section. Any change in authorship (including author order) after the initial article submission must be approved in writing by all authors.

**Originality**

By submitting your article to Reconstructive Review it is understood that this is an original article and is unpublished work and is not under consideration elsewhere. Plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation is not tolerated by Reconstructive Review. Articles submitted to Reconstructive Review will be checked for originality using CrossCheck.

**Informed Consent**

Patients have a right to privacy that should not be infringed without informed consent. Articles should include a statement that the patient’s written consent was obtained and any information, including illustrations, should be as anonymized as far as possible. Authors should indicate that local ethical committees have approved the design of the work or that it conforms to standards currently applied in the country of origin. The name of the authorizing body should be stated in the paper.

Patients’ identities must be removed in all figures (i.e., x-rays, MRIs, charts, photographs, etc.). Written informed consent is required from any potentially identifiable patient or legal representative, and should be presented in either the Methods section or the Acknowledgements.

**Material Disclaimer**

The opinions expressed in Reconstructive Review are those of the authors and contributors, and do not necessarily reflect those of the editors, the editorial board, JISRF, or the organization to which the authors are affiliated.

**Conflict-of-Interest, Disclosures**

As part of the online submission process, corresponding authors are required to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, the authors in question will then be required to submit a completed form to the Editorial Office. It is the Corresponding author’s responsibility to ensure that all authors adhere to this policy.

**Charges**

All content published in Reconstructive Review is made freely available online to all under an Open Access model. Currently there are no charges associated with submitting an article to Reconstructive Review for peer-review and publication. There are no subscription fees and all content is available as full text in either PDF and/or HTML.

**Complaints**

This procedure applies to complaints about content of Reconstructive Review as well as the policies, procedures, or actions of Reconstructive Review’s editorial staff. We welcome complaints as they provide an opportunity and a spur for improvement, and we aim to respond quickly, courteously, and constructively.

Our definition of a complaint is as follows:

- The complainant defines his or her expression of unhappiness as a complaint.
- We infer that the complainant is not simply disagreeing with a decision we have made or something we have published but think that there has been a failure of process - for example, a long delay or a rude response - or a severe misjudgment.
- The complaint must be about something that is within the responsibility of Reconstructive Review’s content or process.
Reconstructive Review is aware of the complaints stated below:
1. Authorship complaints
2. Plagiarism complaints
3. Multiple, duplicate, concurrent publication/Simultaneous submission
4. Research results misappropriation
5. Allegations of research errors and fraud
6. Research standards violations
7. Undisclosed conflicts of interest
8. Reviewer bias or competitive harmful acts by reviewers

Policy for Handling Complaints
If the Journal receives a complaint that any contribution to the Journal infringes intellectual property rights or contains material inaccuracies, libelous materials or otherwise unlawful materials, the Journal will investigate the complaint. Investigation may include a request that the parties involved substantiate their claims. The Journal will make a good faith determination whether to remove the allegedly wrongful material. A decision not to remove material should represent the Journal’s belief that the complaint is without sufficient foundation, or if well-founded, that a legal defense or exemption may apply, such as truthfulness of a statement in the case of libel. Journal should document its investigation and decision. We strive to ensure that Reconstructive Review is of the highest quality and is free from errors. However, we accept that occasionally mistakes might happen.

Editorial Complaints Policy
The Managing Editor and staff of Reconstructive Review will make every endeavor to put matters right as soon as possible in the most appropriate way, offering right of reply where necessary. As far as possible, we will investigate complaints in a blame-free manner, looking to see how systems can be improved to prevent mistakes occurring.

Guiding Principles
Our general approach to complaints is that they are a rare but inevitable part of a process that involves putting together complex material at great speed. We accept that we make mistakes and try to treat all complaints with urgency, however small. We believe that timely solutions can prevent problems escalating. All substantial errors and complaints are referred to senior executives within the editorial staff as a matter of course.

The procedure outlined below aims to be fair to those making complaints and those complained about. All complaints will be acknowledged (within three working days if by email). If possible a definitive response will be made within two weeks. If this is not possible an interim response will be given within two weeks. Interim responses will be provided until the complaint is finally resolved. If the complainant remains unhappy, complaints should be escalated to the editor, whose decision is final.

How to Make a Complaint
Complaints about editorial content should be made as soon as possible after publication, preferably in writing by email to: editors@ReconstructiveReview.org. Please write your complaint with journal title, vol. no., issue no., paper title, and page no.

Corrections, Retractions, and Expressions of Concern
JISRF, Reconstructive Review and its editors take all reasonable steps to identify and prevent the publication of papers where research misconduct has occurred, including plagiarism (all submissions screened using Ithenticate®), citation manipulation, and data falsification/fabrication, among others. In no case does Reconstructive Review or its editors encourage such misconduct, or knowingly allow such misconduct to take place. In the event that Reconstructive Review’s publisher or editors are made aware of any allegation of research misconduct relating to a published article in the journal, JISRF and the senior editorial staff shall follow COPE’s guidelines in dealing with allegations. In addition, Reconstructive Review utilizes a service provided by Crossref called Crossmark. This service gives readers quick and easy access to the current status of a piece of content. With one click, you can see if content has been updated, corrected or retracted.

The issue of conflict of interest and what and how to disclose will be an ongoing area of concern and debate for years to come.

The following quote from Phyllis Pettit Nassi clearly states the challenge. “When you talk about trust you have to know the way a group thinks, how they interact, how they communicate, how they educate. You have to know what their roles and relationships are. What are their values? Their practices? What are the expected behaviors?”

Members of JISRF and Reconstructive Review will stay diligent with regard to COI and disclosure issues and from time to time will update our policies and procedures. We welcome comments on this subject and look forward to addressing concerns within a common sense approach.
Perhaps you were a patient and you were able to regain an important part of your life. Or, perhaps you are simply someone interested in medical research and seeking a new way to participate. Whatever the case, your generosity in helping to fund research is critical to our success - and much appreciated.

The Joint Implant Surgery & Research Foundation is a not-for-profit 501(c)(3) corporation. Your contributions enable scientific discoveries that will help future patients. Contributions over the years from people like you have helped to shape orthopaedics today.

**Contributions**
Donations of any amount will immediately be put to use to fund ongoing and future orthopaedic research projects.

**How to Give**
- Your gift of cash, securities or other negotiable assets is immediately put to use in our research.
- Your contributions are fully tax deductible as specified under Section 501(c)(3) regulations.

For more information please visit our website at www.jisrf.org or contact us at:

**Joint Implant Surgery & Research Foundation**
46 Chagrin Shopping Plaza, #117
Chagrin Falls, OH 44022
440.785.9154
Signature Orthopaedics is a design, development and manufacturing company for orthopaedic implants and instruments. The head office located in Sydney Australia, with offices in Europe and North America. We have years of experience in taking concepts right through design and development and into certification, whether it be the FDA, BSI or the TGA.

We are routinely supplying parts for the Hip, Knee, foot and ankle, spine, shoulder, both to the locally and international markets. With the added capability of making custom implants for specific cases, using the latest software to guarantee the perfect fit.

We are happy to design and develop both instruments and prosthesis for your needs, or we can supply one of our many FDA approved solutions as an OEM vendor.

Our product, your box!

Call or email to discuss which solution is right for you!
JISRF Mission Statement

The specific and primary endeavors are to operate for scientific purposes by conducting medical research of potential improvements in medical surgical methods and materials for preserving and restoring the functions of the human body joints and associated structures which are threatened or impaired by defects, lesions or diseases.

This Journal as all activities conducted by JISRF are available to all interested surgeons, scientists and educators. Our focus is on new cutting edge technologies, science – all with the intent to raise the level of discussion and discovery. Please become a part of this endeavor, we look forward to your interest and participation.

BRENNAN, MANNA & DIAMOND is known nationally for its experience and expertise in Healthcare & Hospital Law.

From physicians to hospital medical staff, from home healthcare providers to allied health professionals and everything in between, BMD can develop and implement strategic plans specifically designed to help you meet and navigate the ever changing healthcare environment.

We serve as legal counsel AND as business and strategic advisors to our healthcare clients.

We give our clients peace of mind so they can get back to the business of caring for their patients.

For more information contact our Health Law Department
75 E. Market Street, Akron, OH 44308 • (330) 253-5060 • www.bmdllc.com
SuperCable®
Polymer Cerclage System

This unique polymer cable eliminates one possible source of metal debris and metal ions in your patient’s fracture or reconstructive procedure. Metal cables have been shown to suffer from significant rates of fatigue failure and to contribute to the generation of local and systemic metallic debris burden.1,2

Laboratory testing demonstrates that the remarkably tough SuperCable withstands over one million load cycles while fully tensioned and abraded by a simulated bone plate, with negligible damage to the cable and metal plate.3

SuperCable has no sharp ends to irritate patient tissue, cut gloves, or create a “sharps injury” risk.

With over 50,000 cables used in cases worldwide since 2004, SuperCable has demonstrated its clinical effectiveness4,5,6 and offers significant benefit versus old technology metal cable and wire.

Levels of Evidence

Reconstructive Review has adopted the American Academy of Orthopaedic Surgeons (AAOS) Levels of Evidence for Primary Research Question. These guidelines will now be part of the review process for manuscript submission.

<table>
<thead>
<tr>
<th>Types of Studies</th>
<th>Therapeutic Studies – Investigating the results of treatment</th>
<th>Prognostic Studies – Investigating the effect of a patient characteristic on the outcome of disease</th>
<th>Diagnostic Studies – Investigating a diagnostic test</th>
<th>Economic and Decision Analyses – Developing an economic or decision model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level I</td>
<td>• High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals • Systematic review of Level I RCTs (and study results were homogenous)</td>
<td>• High quality prospective study (all patients were enrolled at the same point in their disease with ≥80% follow-up of enrolled patients) • Systematic review of Level I studies</td>
<td>• Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference “gold” standard) • Systematic review of Level I studies</td>
<td>• Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses • Systematic review of Level I studies</td>
</tr>
<tr>
<td>Level II</td>
<td>• Lesser quality RCT (e.g. &lt;80% follow-up, no blinding, or improper randomization) • Prospective comparative study • Systematic review of Level II studies or Level I studies with inconsistent results</td>
<td>• Retrospective comparative study • Untreated controls from an RCT • Lesser quality prospective study (e.g. patients enrolled at different points in their disease or &lt;80% follow-up.) • Systematic review of Level II studies</td>
<td>• Development of diagnostic criteria on consecutive patients (with universally applied reference “gold” standard) • Systematic review of Level II studies</td>
<td>• Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses • Systematic review of Level II studies</td>
</tr>
<tr>
<td>Level III</td>
<td>• Case control study • Retrospective comparative study • Systematic review of Level III studies</td>
<td>• Case control study</td>
<td>• Study of non-consecutive patients; without consistently applied reference “gold” standard • Systematic review of Level III studies</td>
<td>• Analyses based on limited alternatives and costs; and poor estimates • Systematic review of Level III studies</td>
</tr>
<tr>
<td>Level IV</td>
<td>Case Series</td>
<td>Case series</td>
<td>• Case-control study • Poor reference standard</td>
<td>• Analyses with no sensitivity analyses</td>
</tr>
</tbody>
</table>

1. A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.
2. A combination of results from two or more prior studies.
3. Studies provided consistent results.
4. Study was started before the first patient enrolled.
5. Patients treated one way (e.g. cemented hip arthroplasty) compared with a group of patients treated in another way (e.g. uncemented hip arthroplasty) at the same institution.
6. The study was started after the first patient enrolled.
7. Patients identified for the study based on their outcome, called “cases”; e.g. failed total arthroplasty, are compared to those who did not have outcome, called “controls”; e.g. successful total hip arthroplasty.
8. Patients treated one way with no comparison group of patients treated in another way.
Reconstructive Review Disclosure Statement

The following information will be published on each paper.

Please check one or more if pertinent of the following:

☐ 1. No benefits or funds were received in direct or indirect support of this article.
☐ 2. Benefits or funds were received in support of this article either directly or indirectly.
☐ 3. Either family, institution I am associated with, or I have received benefits or funds either directly or indirectly regarding this article.
☐ 4. Describe:

Author’s Signature: _____________________________________ (Typed signature is valid for online submission.)

Joint Implant Surgery & Research Foundation www.jisrf.org

Conflict of Interest Statement JISRF
Orthopaedic Industry Affiliations (Past & Present)

Many Authors, Co-Authors, JISRF, or its Members have had affiliations past or present with one or more of these organizations.

AAHKS
AAOS
American Society of Biomechanics
Apex Surgical
Australian Orthopaedic Association
Bactrin International, INC.
Concept Design & Development, DePuy
Dow Corning Wright
Encore Medical
E.M. Warburg, Pincus & Co., LLC
Global Orthopaedic Technology
Harrington Arthritis Research Center
Howmedica
ISTA
Johnson & Johnson
Joint Medical Products Corp.
Kirschner
Kenessis Medical, Inc
Montreal General Hospital Orthopaedic Lab
NASA
ORS
OrthoDevelopment
OTI
Richards Manufacturing
Signature Orthopaedics
Smith & Nephew, Inc.
Society for Biomaterials
Zimmer

Disclosure Statement

JISRF and the Reconstructive Review take disclosure very serious and often readers don’t appreciate the indirect benefit writers receive in publications. Many of our contributors are officially associated with JISRF by the membership on study groups, editorial committee and or clinical / surgical advisors. JISRF is dependent on donations and commercial funding. The overall success of this funding benefits indirectly all that are associated with activities produced by JISRF.

Disclosure for Authors

Article 1, page 11.
Buch [1]; Schroeder [1]; Buch [1]; Eberle [1]

Article 2, page 17.
Durbhakula S [3]; Durbhakula V [1]; Durbhakula N [1]

Article 3, page 23.
Venet [3]; Tesson [1]; Le Cour Grandmaison [1]; Fraquet [1]; Brazil [3]; McTighe [3]

Article 4, page 31.
Martin [1]; Otero [1]; Springer [1]; Griffin [1]

Article 5, page 37.
McTighe [1]